Replies to post #91005 on Enzolytics Inc (ENZC)

[Dodgeball]

There is that, too. But again the entries in the filings are vague. There is significant difference between "entered" and "completed." Unfortunately, $ENZC financials are not always easy to parse, and there is no filing by $IMMB which would detail the receipt of common stock in $ENCZ or a secured note receivable since the last filing on record is December 31, 2016. Looking at the March 31 $ENZC balance sheet, one can see "Stock issued for purchase of subsidiary" as of December 31, 2016 consisting of 60MM Preferred Series A and 100MM Preferred Series B while the 60MM Series A remain. In the entries for December 31, 2017, the 100MM Preferred Series B were cancelled. However there are 175MM shares of Common Stock issued for "license," and 211MM shares of Common issued for "asset purchase" for a total of 386MM common shares. So potentially there was a payment of 386MM common shares, about 18% of current float. But no mention of a secured note receivable nor it's value.

Challenging to parse, and still a bit murky.

On March 26, 2018 an asset purchase agreement was entered with Immunotech Laboratories, Inc whereby the Exclusive
License Agreement for the Patented Immunotherapy Treatment for the care of HIV/Aids and Hepatitis C patients, the Forty
Nine Percent ownership in Immunotech Laboratories BG, all equipment and licensing of intellectual property associated
with the Patented treatment in exchange for a secured note receivable, common stock of Enzolytics, Inc. issued to
Immunotech Laboratories, Inc. and assumption of certain debt from Immunotech by Enzolytics, Inc